{"nct_id":"NCT02394561","title":"A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)","status":"COMPLETED","status_verified_date":"2019-04","start_date":"2015-04-10","start_date_type":"ACTUAL","primary_completion_date":"2017-06-08","primary_completion_date_type":"ACTUAL","completion_date":"2017-06-08","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["NVS"]}